The Food and Drug Administration today announced it is requesting manufacturers immediately withdraw all prescription and over-the-counter ranitidine drugs (commonly known by the brand name Zantac) from the market.

This is the latest step in an ongoing investigation of the carcinogenic contaminant N-Nitrosodimethylamine (NDMA), which in some ranitidine products increases over time and when stored at higher than room temperatures to unacceptable levels.

The FDA advised consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine.

Related News Articles

Headline
The Health Insurance Marketplace for the District of Columbia is encouraging labs to remove race as a variable in the estimated glomerular filtration rate (…
Perspective
Patient safety and top-notch patient care have always been the twin guide stars of our field. Hospitals and health systems have led the way in making bold…
Headline
More than 100 organizations, including the AHA, urged congressional leaders Nov. 14 to reauthorize for an additional five years the Pandemic and All-Hazards…
Headline
The AHA, AHIP, Alliance of Community Health Plans, American Medical Association and Kaiser Permanente have formed a coalition that will recommend strategies to…
Headline
Two maternal health experts explore common disparities and systemic barriers Indigenous people experience in pregnancy and postpartum, and ways hospitals and…
Blog
In health care, where decisions can be life-altering and regulatory policies help shape care quality and delivery, board members play a pivotal role in…